 <b>TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT</b> (Under 37 CFR 1.97(b) or 1.97(c))					Docket No. <b>114309-1007</b>	
In Re Application of <b>Gerald Horn</b>						
Application No. <b>09/854,414</b>	Filing Date <b>May 10, 2001</b>	Examiner <b>Z. Fay</b>	Customer No. <b>24573</b>	Group Art Unit <b>1614</b>	Confirmation No. <b>7675</b>	
Title: <b>OPHTHALMIC FORMULATIONS COMPRISING IMIDAZOLINE</b>						
Address to: <b>Commissioner for Patents</b> <b>P.O. Box 1450</b> <b>Alexandria, VA 22313-1450</b>						
<b>37 CFR 1.97(b)</b>						
1. <input type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.						
<b>37 CFR 1.97(c)</b>						
2. <input checked="" type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:						
<div style="margin-left: 40px;"> <input type="checkbox"/> the statement specified in 37 CFR 1.97(e);         </div>						
<b>OR</b>						
<div style="margin-left: 40px;"> <input checked="" type="checkbox"/> the fee set forth in 37 CFR 1.17(p).         </div>						

P10A/REV05

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /ZF/

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.  
114309-1007

Re Application: Gerald Horn

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
09/854,414	May 10, 2001	Z. Fay	24573	1614	7675

Title: OPTHALMIC FORMULATIONS COMPRISING IMIDAZOLINE

**Payment of Fee**

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of \_\_\_\_\_ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. 02-1818 as described below.
- ☒ Charge the amount of \$180.00
  - ☒ Credit any overpayment.
  - ☒ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**

**Certificate of Transmission by Facsimile\***

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. \_\_\_\_\_)

\_\_\_\_\_  
(Date)

\_\_\_\_\_  
Signature

\_\_\_\_\_  
Typed or Printed Name of Person Signing Certificate

**Certificate of Mailing by First Class Mail**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

October 11, 2005

\_\_\_\_\_  
(Date)

\_\_\_\_\_  
Signature of Person Mailing Correspondence  
Heather Foster

\_\_\_\_\_  
Typed or Printed Name of Person Mailing Certificate

\*This certificate may only be used if paying by deposit account.

Dated: October 11, 2005

\_\_\_\_\_  
Signature

Thomas C. Basso (46,541)  
Cust. No. 29175

cc:



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Gerald Horn  
Appl. No.: 09/854,414  
Conf. No.: 7675  
Filed: May 10, 2001  
Title: OPTHALMIC FORMULATIONS COMPRISING IMIDAZOLINE  
Art Unit: 1614  
Examiner: Z. Fay  
Docket No.: 114309-1007

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Sir:

In accordance with the provisions of 37 C.F.R. 1.56, 37 C.F.R. 1.97, and 37 C.F.R. 1.98, Applicants request that a citation and examination of the references cited below, and on the attached PTO-1449 form be made during the course of examination of the above-identified application for United States patent. Pursuant to 37 C.F.R. 1.98, copies of all foreign patent documents and non-patent documents are enclosed.

**U.S. PATENT DOCUMENTS**

<u>Document No.</u>	<u>Date</u>	<u>Inventor</u>
6,730,691	May 4, 2004	Galin

Applicants look forward to early and favorable consideration of this matter.

Respectfully submitted,

BELL, BOYD & LLOYD LLC


BY 

Thomas C. Basso (46,541)  
Cust. No. 29175

Dated: October 11, 2005

10/17/2005 YPOLITE1 00000048 021818 09854414

02 FC:1806 180.00 DA



<b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b> (Use several sheets if necessary)  PTO Form 1449	Atty Docket No. 114309-1007	Application No. 09/854,414
	Applicant Gerald Horn	
	Filing Date May 10, 2001	Group 7675

### U.S. PATENT DOCUMENTS

Examiner's Initials	Document Number	Publication Date	Inventor	Class	Subclass	Filing Date If Appropriate
	6,730,691	May 4, 2004	Galin			

### FOREIGN PATENT DOCUMENTS

Examiner's Initials	Document Number	Publication Date	Country	Class	Subclass	Translation	
						Yes	No

### OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Examiner's Initials	

Examiner: /Zohreh Fay/ (05/11/2011)	Date Considered:
*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	